Peptide education
GHRP-6
GHRP-6 is one of the oldest growth-hormone secretagogues still sold online: a six-amino-acid synthetic peptide that pushes the ghrelin receptor and makes the pituitary release growth hormone. That effect is real, and small human studies in the 1980s and 90s measured it repeatedly. Everything else people buy it for (muscle, fat loss, recovery, better sleep, slower aging) is an extrapolation from that one documented pulse, not something those studies ever measured.
Small human studies prove GHRP-6 can move growth hormone for a few hours. Nothing they measured says what that pulse does for muscle, waistline, sleep, or recovery.
Overview
Quick answer
GHRP-6 is not tesamorelin, pralmorelin, ipamorelin, CJC-1295, or a labeled growth-hormone product. The main GHRP-6 sources are older endocrine challenge, diagnostic, pediatric physiology, sleep, mechanism, and pharmacokinetic studies. Clinic pages, vendor listings, protocol blogs, and forum discussions often use the same name for unapproved or research-use vials, which creates a separate product-quality problem.
What is GHRP-6?
GHRP-6 is a six-amino-acid growth hormone secretagogue. Instead of being growth hormone itself, it stimulates the body's GH axis through the ghrelin receptor and related hypothalamic-pituitary signaling.
Why is it discussed?
Because a GH pulse sounds like it should matter for muscle, fat, sleep, and aging. The studies behind that reputation are small endocrine experiments: they watched the hormone rise and fall, not anyone's body composition, strength, or recovery.
What routes and schedules show up?
Human research used controlled IV, oral, diagnostic, and pharmacokinetic exposures. Clinic, vendor, and forum sources discuss cycles, stacks, appetite, and physique goals, but those are market reports, not settled public-use schedules.
What can a GH pulse tell you?
A GH pulse tells you the pituitary responded. It helps explain the appetite, body-composition, sleep, recovery, and aging conversation, but it does not measure those outcomes by itself. Most public use claims come from clinics, vendors, online protocol posts, forums, or gray-market discussion rather than modern controlled outcome trials.
Reported practice
Commonly reported protocol
Clinic and wellness GH-secretagogue use. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Older human physiology studies repeatedly reported GH increases after GHRP-6 exposure, including dose-response work and synergy with GHRH. Those studies measured short-term endocrine responses, not body transformation.
GHRP-6 binds the ghrelin receptor, which makes appetite discussion biologically plausible. Direct human appetite outcome data for GHRP-6 are still sparse.
Muscle, fat-loss, performance, recovery, and anti-aging claims are common in clinic and vendor language, but the human literature is mostly challenge, diagnostic, sleep, and pharmacokinetic work.
FDA materials raise concerns about compounded GHRP-6 safety, peptide impurities, aggregation, sterility failure in a sermorelin/GHRP-6 recall, and online products sold under research-use labels.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| GHRP-6 increases growth hormone. | This statement is well supported. Healthy-volunteer, obesity physiology, pediatric physiology, mechanism, and diagnostic studies reported GH responses after GHRP-6 exposure under monitored conditions. | GHRP-6 activates the ghrelin receptor and interacts with endogenous GHRH tone. Antagonist and disconnection studies suggest the response involves more than a direct pituitary switch. | Clinic and vendor marketing often starts with the GH effect and turns it into broader wellness language, usually without showing controlled outcome data for those broader goals. | Supported as an acute endocrine effect. That hormone bump is still not physique, recovery, or anti-aging evidence. |
| GHRP-6 builds muscle or improves performance. | The human studies are endocrine challenge, diagnostic, sleep, or pharmacokinetic studies. They do not test lean-mass gain, strength, or training performance as controlled outcomes. | GH and IGF-1 biology can affect tissue remodeling and substrate handling, which explains why the claim travels with secretagogues. | Muscle and performance language appears in clinic, vendor, protocol-blog, and gray-market discussion, but those materials usually lack controlled outcomes, verified products, and follow-up. | A popular extrapolation from GH-axis biology, not a demonstrated GHRP-6 outcome in the human evidence. |
| GHRP-6 burns fat. | The human evidence does not identify a direct GHRP-6 fat-loss efficacy program. Tesamorelin's labeled visceral-fat evidence comes from a different drug. | GH-axis biology can influence lipolysis and body composition, but hormone movement alone is not the same as measured fat loss in real users. | Clinic and gray-market pages often frame GHRP-6 near body recomposition, cutting, and fat loss. Those sources show marketing and online-use signals rather than clinical outcomes. | The cited human literature is mainly acute endocrine context, not a fat-loss outcome program. |
| GHRP-6 increases appetite. | Direct GHRP-6-specific human appetite outcome data are sparse. The appetite claim is not as well documented as the short-term GH response. | GHRP-6 binds the ghrelin receptor, the same receptor family tied to hunger signaling, so appetite discussion is biologically plausible. | Appetite language appears in clinic and vendor examples and is part of how GHRP-6 is discussed online, especially compared with other GH secretagogues. | Plausible and commonly discussed, but not well quantified as a GHRP-6 clinical outcome in the cited evidence. |
| GHRP-6 improves sleep or recovery. | Small human sleep studies reported GH, ACTH, cortisol, and sleep-related changes. Those measurements do not tell whether someone recovers faster, feels more rested, or adapts better to training. | The GH axis and sleep physiology interact, and GHRP-6 can have neuroendocrine spillover beyond GH under some study conditions. | Recovery and sleep claims are common in wellness and online protocol discussions, usually without consistent product identity or follow-up. | These studies are useful for endocrine-sleep physiology, but they do not show better sleep or recovery. |
| A research-use vial with a COA is equivalent to studied GHRP-6. | Human studies do not show that retail or gray-market products match the material, purity, sterility, or dosing conditions used in research settings. | This is a quality question, not a receptor question. Identity, aggregation, peptide-related impurities, endotoxin, sterility, concentration, storage, and finished-vial accuracy all matter. | Vendor pages may show purity percentages, mass-spectrometry references, downloadable COAs, or research-use labels. FDA warning letters show that those labels still leave concerns when marketing points toward use in people. | A COA is a narrow analytical document, and clinical-grade injectable quality needs more than that. |
Bottom line
Main takeaway
GHRP-6 is a GH secretagogue with real short-term hormone effects and no solid human outcome data for muscle, fat-loss, recovery, sleep, or anti-aging use.
Keep GHRP-6 separate from tesamorelin, pralmorelin/GHRP-2, ipamorelin, CJC-1295, and HGH. The molecule, route, product oversight, and supporting evidence change when the name changes.
The strongest sources are the older human endocrine studies, diagnostic testing papers, sleep-endocrine studies, PK work, ghrelin-receptor structure paper, and FDA compounding materials. They support GH-axis activity and safety concerns, not broad wellness outcomes.
Identity
What it is
GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It is part of the growth hormone secretagogue family and is described in older literature as growth hormone-releasing hexapeptide or SKF-110679.
It works differently from GHRH analogs. Structural and signaling papers place GHRP-6 at the ghrelin receptor, while classic physiology studies show interaction with endogenous GHRH tone.
It is discussed because GH release sounds connected to physique and recovery. The better reading is narrower: acute hormone movement is documented, while long-term body-composition and performance outcomes are not.
The online market mixes clinic wellness copy with research-use vial listings. Clinic and wellness pages talk about appetite, muscle, recovery, sleep, vitality, and anti-aging, while vendors sell research-use vials with purity and COA language.
How people talk about it online
Clinic and wellness pages usually present GHRP-6 as a GH-axis peptide for appetite, muscle, recovery, sleep, vitality, or body composition. That material shows what sellers are promising, not what controlled outcome trials have measured.
Vendor pages and gray-market listings commonly use research-use-only language, lyophilized-vial descriptions, purity percentages, HPLC or MS references, and downloadable COAs. Those details still do not answer sterility, endotoxin, concentration, finished-vial accuracy, or clinical oversight.
Forum posts and online protocol discussions often treat GHRP-6 as part of the broader GH secretagogue family and compare it with GHRP-2, ipamorelin, sermorelin, CJC-1295, or tesamorelin. Those comparisons only help when molecule-specific evidence stays separate.
Use context
Routes, doses, and cycle patterns
The most concrete GHRP-6 schedules here come from monitored research, not modern product labels. Study conditions include IV infusion or bolus dosing, oral pediatric physiology dosing, combination testing with GHRH, and pharmacokinetic boluses. Real-world clinic, vendor, forum, and gray-market sources discuss injectable use, cycles, stacks, appetite, and physique goals, but they do not give an amount or schedule for non-clinical use.
Human studies and product labels
Healthy-men dose-response physiology
- Purpose
- Acute GH release
- Context
- Human physiology study
- Route
- Intravenous infusion
- Amount
- 0.05 to 2.5 micrograms/kg
- Frequency
- Single 30-minute infusion under study conditions
- Duration
- Acute sampling period
The study reported a dose-dependent GH rise with a peak around 45 minutes and no LH, FSH, TSH, or ACTH change under that specific daytime protocol.
Obesity physiology with GHRH comparison
- Purpose
- GH response and GHRH synergy
- Context
- Human physiology study
- Route
- Intravenous
- Amount
- GHRP-6 100 micrograms, alone or with GHRH 100 micrograms
- Frequency
- Single challenge conditions
- Duration
- Acute endocrine testing
In obese subjects, GHRP-6 produced more GH than GHRH alone, and the GHRP-6 plus GHRH combination produced strong synergy. This was still a hormone endpoint, not a fat-loss study.
Oral pediatric short-stature physiology
- Purpose
- GH response testing
- Context
- Small pediatric physiology study
- Route
- Oral
- Amount
- 300 micrograms/kg
- Frequency
- Single study exposure
- Duration
- Acute endocrine testing
In 13 children with normal short stature, oral GHRP-6 increased GH secretion to an extent similar to maximally effective IV GHRH. The study did not test growth outcomes.
GHRH-antagonist mechanism study
- Purpose
- Mechanism of GH response
- Context
- Human antagonist study
- Route
- Intravenous bolus
- Amount
- GHRP-6 1 microgram/kg after GHRH antagonist 400 micrograms/kg
- Frequency
- Single challenge protocol
- Duration
- Acute endocrine testing
Blocking endogenous GHRH removed most of the GH response to GHRP-6, which argues that endogenous GHRH tone matters for the effect.
Adult GH-deficiency diagnostic testing
- Purpose
- Historical adult GH-deficiency testing
- Context
- Diagnostic endocrinology studies
- Route
- Route varies by diagnostic study; related rows describe IV challenge contexts
- Amount
- GHRP-6 1 microgram/kg alone or with GHRH 1 microgram/kg
- Frequency
- Separate testing days in reported diagnostic work
- Duration
- Acute diagnostic testing
Adult diagnostic papers compared GHRP-6 or GHRP-6 plus GHRH with insulin tolerance testing. Later work warned that severe obesity can lower responses enough that fixed cutoffs do not carry across populations.
Healthy-volunteer pharmacokinetics
- Purpose
- PK measurement
- Context
- Human pharmacokinetic study
- Route
- Intravenous bolus
- Amount
- 100, 200, and 400 micrograms/kg
- Frequency
- Single bolus doses
- Duration
- PK sampling after each exposure
The study characterized GHRP-6 pharmacokinetics with LC-MS methods. It was not an efficacy study.
Real-world discussion
Clinic and wellness GH-secretagogue use
- Purpose
- Appetite, muscle, recovery, sleep, vitality, and body-composition claims
- Context
- Clinic and wellness pages
- Route
- Usually discussed as injectable peptide use
- Amount
- Most reports describe 100 to 300 mcg per injection, two to three times daily, often timed before meals because of the hunger effect.
- Frequency
- Two to three times daily in most community descriptions
- Duration
- Commonly described in 8 to 12 week cycles
Clinic-style claims start from the GH secretagogue effect and move into broader wellness outcomes. The schedules above are community conventions; the cited human studies do not establish a wellness or body-composition protocol.
Vendor and gray-market vial listings
- Purpose
- Research-use peptide sales and product comparison
- Context
- Vendor listing and gray-market use
- Route
- Marketed as lyophilized vial material; human route claims vary by surrounding marketing
- Amount
- Vial amounts commonly 5 or 10 mg; community math maps this to the 100 to 300 mcg per-injection convention
- Frequency
- Community schedules mirror the two to three times daily convention
- Duration
- Commonly described in 8 to 12 week cycles
Vendor listings may show purity percentages, HPLC or mass-spectrometry language, research-use disclaimers, and COAs. FDA warning letters and compounding materials still do not answer approval, sterility, endotoxin control, finished-vial accuracy, or suitability for human use.
Forum GH peptide comparisons
- Purpose
- Comparing GHRP-6 with GHRP-2, ipamorelin, sermorelin, CJC-1295, and tesamorelin
- Context
- Forum, protocol-blog, and gray-market discussion
- Route
- Usually discussed around injectable secretagogue stacks
- Amount
- Community stack descriptions commonly place GHRP-6 at 100 to 300 mcg per injection alongside a GHRH analog
- Frequency
- Two to three times daily in stack descriptions
- Duration
- Commonly 8 to 12 weeks in stack descriptions
These discussions often blur different GH-axis peptides. Keep GHRP-6 separate from tesamorelin's labeled visceral-fat data, pralmorelin's diagnostic status, ipamorelin's selectivity claims, and CJC-1295 schedules.
What varies
- Goal: GH release, appetite, muscle, fat loss, sleep, and recovery are different outcome questions.
- Source: endocrine challenge studies show hormone response; clinic, vendor, and forum sources show sales or use patterns; FDA warning letters speak to regulatory and product-quality risk.
- Route: the human research includes IV and oral study conditions; gray-market discussion usually centers on injectable vials.
- Amount: study amounts are documented in micrograms/kg or fixed microgram IV challenges, but they do not give an amount or schedule for non-clinical use.
- Product quality: identity, aggregation, impurities, sterility, endotoxin, concentration, storage, and finished-vial accuracy matter for any injectable peptide.
Human data
Human evidence
Human evidence for GHRP-6 is real but narrow. The best-supported findings are short-term GH release, GHRH synergy, historical diagnostic behavior, sleep-endocrine effects, and pharmacokinetics. It does not include modern controlled outcome trials for muscle gain, fat loss, performance, recovery, anti-aging, or routine appetite treatment.
Evidence maturity
GHRP-6 has solid human endocrine documentation and a solved binding structure, and zero outcome trials for the marketed uses.
Dose-response GH release, GHRH synergy, and historical diagnostic work.
2021 cryo-EM structure of GHRP-6 bound to the human ghrelin receptor.
None for muscle, fat loss, recovery, or anti-aging.
Gray-market vials and class-wide FDA scrutiny of secretagogues.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Healthy-men dose-response physiology | 17 healthy men | Human endocrine challenge study | Research peptide under monitored study conditions | A 30-minute IV infusion from 0.05 to 2.5 micrograms/kg produced a dose-dependent GH rise, with a peak near 45 minutes. | Acute hormone response only; no body-composition, appetite, strength, recovery, or long-term safety endpoints. | moderate |
| Oral GH-release physiology | Normal men and children with normal short stature in separate older studies | Human physiology studies | Research peptide under study conditions | Oral GHRP-6 stimulated GH secretion in older human work, including a pediatric study using 300 micrograms/kg. | The evidence is acute physiology, not growth, body-composition, or general wellness efficacy. | weak |
| GHRH interaction and diagnostic testing | Obese adults, healthy men, children with hypothalamic disconnection, and adults assessed for GH deficiency | Human endocrine mechanism and diagnostic studies | Research peptide and diagnostic-testing context | GHRP-6 interacted strongly with GHRH pathways. Studies reported synergy with GHRH, blunted responses in hypothalamic-disconnection settings, and historical diagnostic-testing performance. | Diagnostic and mechanism studies are not therapeutic-benefit studies, and obesity can change response thresholds. | moderate |
| Sleep-endocrine studies | Small human sleep-study cohorts | Human sleep and neuroendocrine studies | Research peptide under sleep-lab conditions | GHRP-6 could stimulate GH, ACTH, cortisol, and sleep-related changes depending on dose, duration, route, and timing. | These studies measure overnight endocrine and sleep-architecture changes, not whether users sleep better, recover faster, or improve training outcomes. | weak |
| Healthy-volunteer PK | 9 healthy male volunteers | Human pharmacokinetic study | Research peptide measured with LC-MS methods | Single IV bolus doses of 100, 200, and 400 micrograms/kg were used to characterize pharmacokinetics. | PK characterization is not an efficacy or safety package for real-world repeated use. | weak |
Cautions
Safety and unknowns
- Long-term safety remains open because the human literature is mostly acute physiology, diagnostic, sleep, and PK work.
- GHRP-6 is not a clean GH-only switch. Human sleep studies reported ACTH, cortisol, and sleep-related effects under some conditions, and FDA materials note cortisol-related and glucose-related concerns.
- FDA materials describe limited safety information for compounded GHRP-6 and concerns about immunogenicity from aggregation and peptide-related impurities.
- Continuous or prolonged exposure studies reported partial response attenuation, which keeps desensitization and repeated stimulation questions open.
- Injectable gray-market or clinic supply raises risks that old endocrine studies do not answer: sterility, endotoxin, concentration, impurities, storage, reconstitution, and product substitution.
Product quality
A vial label is only a starting point
Vendor COAs and purity percentages are partial analytical claims, and clinical-grade injectable quality needs more than that.
FDA has described safety concerns for compounded GHRP-6 and documented a sermorelin/GHRP-6 injection recall tied to sterility failure.
Research-use-only language does not settle the product-quality issue when the surrounding marketing points toward human use.
Identity
The first question is whether the vial actually contains GHRP-6 rather than a related secretagogue, different peptide, wrong salt form, or mislabeled amount.
Aggregation and peptide impurities
FDA's GHRP-6 concerns include immunogenicity risk from aggregation and peptide-related impurities, which headline purity percentages may not answer.
Sterility and endotoxin
For injectable material, a COA that focuses on identity or purity still leaves sterile finished-vial quality to be documented.
Concentration and dose math
Study doses are often micrograms/kg under monitored conditions. A gray-market vial requires separate answers about fill amount, reconstitution, concentration, and measurement accuracy.
Mechanism
How it is proposed to work
GHRP-6 mimics part of ghrelin-like signaling at the ghrelin receptor, which can stimulate the pituitary growth-hormone axis. That explains the acute GH response and the appetite discussion, but not long-term body or recovery outcomes.
A 2021 cryo-EM study showed GHRP-6 bound to the human ghrelin receptor, helping explain how a small synthetic hexapeptide can activate a receptor normally associated with ghrelin.
Classic signaling work contrasts GHRP-6 with GHRH: GHRH is tied to cAMP and protein kinase A signaling, while GHRP-6 is associated with phosphoinositide and protein kinase C pathways plus intracellular calcium mobilization.
Human antagonist and hypothalamic-disconnection studies show that GHRP-6 is not fully independent of endogenous GHRH tone. The GH response depends on an intact hypothalamic-pituitary system.
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) binds the ghrelin receptor directly, confirmed by a 2021 cryo-EM structure. Antagonist studies show its GH effect depends substantially on intact endogenous GHRH tone, which is why it is best understood as amplifying the axis rather than switching it.
FAQ
Common questions
Does GHRP-6 build muscle or burn fat?
The human studies show acute growth-hormone release, not body-composition outcomes. Muscle, fat-loss, and anti-aging claims are extrapolations from that hormone effect, and no controlled trials test them.
Why does GHRP-6 increase hunger?
It activates the ghrelin receptor — the same receptor that drives hunger signaling. Appetite stimulation is a direct pharmacological effect, which is why GHRP-6 is discussed for eating support as much as for GH.
What do people report using?
Community protocols commonly describe 100 to 300 mcg per injection, two to three times daily, often timed before meals, in 8 to 12 week cycles.
Details
Technical details
Sources
References
- 1.
Ilson dose-response. Ilson et al., 1989, JCEM. In 17 healthy men, 30-minute IV infusion of the hexapeptide produced a dose-dependent GH rise, with serum LH, FSH, TSH, and ACTH unaffected under that protocol.
- 2.
Hartman oral study. Hartman et al., 1992, JCEM. Oral administration of GH-releasing peptide stimulated GH secretion in normal men, showing oral activity in older human physiology work.
- 3.
Cordido obesity study. Cordido et al., 1993, JCEM. In obese subjects, GHRP-6 at 100 μg IV produced larger GH responses than GHRH alone, and GHRP-6 plus GHRH showed marked synergy.
- 4.
Bellone pediatric oral study. Bellone et al., 1995, European Journal of Endocrinology. In 13 children with normal short stature, oral GHRP-6 at 300 μg/kg increased GH secretion to an extent similar to IV GHRH.
- 5.
Disconnection studies. Pombo et al., 1995, JCEM, and Popovic et al., 1995. In pediatric and adult hypothalamic-disconnection settings, GH responses to GHRP-6 were absent or blunted, arguing against simple pituitary-only action.
- 6.
Pandya antagonist study. Pandya et al., 1998, JCEM. In nine healthy men, a GHRH antagonist eliminated most of the GH response to GHRP-6, showing that endogenous GHRH is necessary for most of the GH effect.
- 7.
Sleep-endocrine studies. Frieboes et al., 1995 and 1999. Human sleep studies showed that GHRP-6 could stimulate GH, ACTH, cortisol, and modify sleep, with effects dependent on dose, duration, route, and timing.
- 8.
Popovic diagnostic test. Popovic et al., 2000, Lancet. The GHRH/GHRP-6 test was reported as a convenient, safe, and reliable historical test for adult GH deficiency.
- 9.
Diagnostic cutoff studies. Petersenn et al., 2002, and Haijma et al., 2005. GHRP-6 alone or with GHRH compared favorably with ITT in one adult study, but later work showed severe obesity lowers responses enough that fixed cutoffs cannot simply be reused.
- 10.
Cabrales PK study. Cabrales et al., 2013, European Journal of Pharmaceutical Sciences. Nine healthy male volunteers received single IV bolus doses of 100, 200, and 400 μg/kg in a pharmacokinetic study using an LC-MS method.
- 11.
Ghrelin receptor structure. Wang et al., 2021, Nature Communications. Cryo-EM structures showed GHRP-6 bound to the human ghrelin receptor and clarified its orthosteric binding mode.
- 12.
FDA safety-risk page. FDA compounded-drug safety-risk page. FDA states compounded GHRP-6 may pose immunogenicity risk because of aggregation and peptide-related impurities, and notes limited safety information plus concerns about cortisol and blood glucose.
- 13.
United Pharmacy letter. FDA United Pharmacy warning letter. FDA states compounded products using GHRP-6 are not eligible for section 503A exemptions because GHRP-6 is not the subject of an applicable monograph, is not a component of an FDA-approved human drug, and is not on the 503A bulks list.
- 14.
Town and Country recall. FDA Town and Country warning letter. FDA acknowledged a voluntary recall of sermorelin/GHRP-6 injection because of sterility failure.
- 15.
FDA seller letters. FDA peptide warning letters to online sellers. FDA states online “research use only” disclaimers do not prevent products from being unapproved or misbranded drugs when the marketing indicates human use, and warns of contamination, counterfeiting, wrong strength, or different ingredients.
- 16.
Approved comparators. Adjacent approved comparators. The FDA-approved tesamorelin label applies to HIV-associated lipodystrophy and explicitly says it is not indicated for weight-loss management; PMDA records pralmorelin hydrochloride, GHRP Kaken 100, as a diagnostic agent for growth-hormone secretory function.
- 17.
Market examples. Gray-market and clinic examples. Current pages market GHRP-6 with “research use only” framing, 99%+ HPLC or MS references, visible COAs, or clinic claims around appetite, muscle, and recovery. These are gray-market examples, not efficacy data.
- 18.
Raun endocrine comparison. Raun et al., 1998. Comparative endocrine work reported that GHRP-6 and GHRP-2 increased ACTH and cortisol, whereas ipamorelin did not, supporting a cleaner selectivity profile for ipamorelin in that context.
- 19.
Pituitary signaling. Pituitary signaling studies and reviews. GHRP-6 triggered biphasic intracellular calcium responses and phosphoinositide signaling, while review literature contrasted GHRP-6 PKC and IP3 signaling with GHRH cAMP and PKA signaling.